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ABSTRACT 
Objectives: The objectives of this research were to develop and validate a HPLC method for determination of Pentoxyverine citrate (PNX) and its 
degradant (DG). 
Methods: Forced degradation studies were performed on bulk sample using alkaline (0.1M sodium hydroxide) and acid (1M hydrochloric acid. The 
proposed method was based on using a 150 x 4.6 mm (i. d.) (Luna, Phenomenex, Torrance, CA, USA) (5 µm particle size) reversed phase C18 column 
with mobile phase consisting of a mixture of methanol-10 mM sodium dihydrogen phosphate pH 4 in ratio of (60:40, v/v) and UV detection at 230 
nm with flow rate of 1 mL min-1. 
Results: The linear calibration range was between 10-40 µg ml-1and 10-40 µg ml-1for PNX and DG respectively. The method was found to be 
accurate with 100.23% and 100.07% recovery for PNX and DG respectively. The limit of detection (LOD) was found to be 3.79 x10-2μg ml-1 and 4.24 
x10-2μg ml-1 for PNX and DG respectively, while the limit of quantification (LOQ) was found to be 12.62 x10-2μg ml-1 and 14.12 x10-2μg ml-1 for PNX 
and DG respectively. PNX was found to be most stable at a pH of 5.7. 
Conclusion: The validation study of the proposed method was successfully carried out and the method was found to be suitable and economic for 
routine determination of PNX in pharmaceutical syrup, without any interference from the excipients, and in the presence of its acidic and alkaline 
degradation products.  
Keywords: RP-HPLC, Pentoxyverine citrate, pH-rate profile, Britton-Robinson buffer. 
 
INTRODUCTION 
Pentoxyverine Citrate (PNX) is 2-[2-(diethylamino)ethoxy]ethyl 1-
phenylcyclopentanecarboxylate dihydrogen 2-hydroxypropane-
1,2,3-tricarboxylate [1]. This drug has atropine-like and local 
anesthetic actions and effectively suppresses acute cough due to 
common upper respiratory infections [2]. Several methods in the 
literature are describing the determination of PNX in dosage forms 
and biological fluid. These methods includes colorimetry [3], 
different sensors and electrodes based on ion-pair complexes [4,5], 
derivative spectrophotometry [6,7] and flow-injection [8]. 
Moreover, separation techniques such as capillary electrophoresis 
[9], HPLC [10,11] and LC–MS were used for the determination of 
PNX in human plasma [12,13]. Syrups containing PNX in 
combination with other drugs was analyzed using HPLC-DAD [14]. 
Furthermore, GC-MS was used for determination of PNX and its 
metabolites in urine [15]. Recently, during the development of this 
work, a HPLC-DAD method, was used for studying the stability of 
PNX. However, the published method [16] did not quantify the 
degradation products or identify them. Therefore, the advantage of 
our developed method over the published one is identifying and 
quantitation of the degradation products. On the other hand, the 
developed HPLC method used isocratic elution while the other 
method used gradient elution. 
The International Conference on Harmonization (ICH) guideline 
entitled ‘stability testing of new drug substances and products’ 
requires that stress testing be carried out to elucidate the inherent 
stability characteristics of the active substance [17]. PNX is an ester 
drug type, which can be easily degraded. The aim of this work was to 
develop stability indicating method for determination of PNX and its 
degradant using LC method. Furthermore, the developed LC method 
was used to investigate the kinetics of the acidic and basic degradation 
processes, and to calculate the activation energy needed for PNX 
degradation. The pH-rate profile of degradation of PNX in Britton–
Robinson buffer solutions within the pH range 2– 12 was studied. 
MATERIALS AND METHODS 
Instrumentation 
The HPLC (Bischoff, Germany), instrument was equipped with a model 
series 2250 LC pump, Rheodyne 7125 injector with a 20 µl loop and a 
LC lambda 1010 variable wavelength spectrophotometric detector 
(Bischoff), Separation and quantitation were made on 150 x 4.6 mm (i. 
d.) (Luna, Phenomenex, Torrance, CA, USA) (5 µm particle size) 
reversed phase C18 column.  
The sample was injected with 25 µl hamilton analytical syringe. Data 
acquisition were performed on model MCDACq data acquisition 
system (version 1.3x). The detector was set at λ 230 nm. A double-
beam shimadzu (Japan) UV-Visible spectrophotometer, model UV-
1601 PC connected to an IBM compatible computer.  
The bundled software was UVPC personal spectroscopy software 
version 3.7 (Shimadzu). The spectral bandwidth was 2 nm and the 
wavelength scanning speed was 2800 nm min-1.  
The IR spectrophotometer used was Shimadzu Spectrophotometer 
Model IR-408. 
PMR spectra were recorded on avarian Gemini 200, 1H-NMR 
Spectrophotometer (200 mega hertz) USA. 
Materials and reagents 
Pharmaceutical grade of PNX (Borg Pharmaceutical industries 
Company, Alexandria, Egypt) was used and certified to contain 
99.8%. Methanol used was HPLC grade (BDH, Poole, UK). Sodium 
hydroxide, phosphoric acid, hydrochloric acid and hydrogen 
peroxide were analytical grade.  
Cabella® syrup (Batch No. 093657)used, was manufactured by Borg 
Pharmaceutical industries Company, Alexandria, Egypt, labeled to 
contain 21.3 mg/10 ml PNX. 
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The HPLC separation and quantitation were made on a 150 x 4.6 mm 
(i. d.) (Luna, Phenomenex, Torrance, CA, USA) (5 µm particle size) 
reversed phase C18 column. 
The mobile phase was prepared by mixing methanol and 10 mM 
sodium dihydrogen phosphates, pH adjusted to 4 using sodium 
hydroxide, in the ratio of (60:40 v/v) and UV detection at 230 nm. 
The flow rate was 1 ml min-1. All determinations were performed at 
ambient temperature. The injection volume was 20 μl. 
Preparation of the degradant 
Preparation of the alkali-induced degradant 
Three hundred mg of PNX was firstly dissolved in 50 ml methanol 
and refluxed with 50 ml 0.1M sodium hydroxide at 100 °C for 3 h. 
Subsequently the pH of the solution was adjusted to 4.5 using 1N 
hydrochloric acid to precipitate the degradation product. The 
precipitate was filtered and dried under vacuum. The residue was 
analyzed by IR and NMR and was found to be 1-
phenylcyclopentanecarboxylic acid as a degradant (DG). The filtrate 
was washed 3 times, each with 10 ml chloroform. The washed 
aqueous extract was evaporated and dried under vacuum. The 
residue was analyzed by IR and NMR and found to be 2-
(diethylamino) ethoxy)methanol. 
Preparation of the acid-induced degradant 
Three hundred mg of PNX was firstly dissolved in 50 ml methanol 
and refluxed with 50 ml 1M hydrochloric acid at 100 ºC for 12 h. 
Subsequently the solvent was evaporated. The same procedure, for 
separation of DG previously described under preparation of the 
alkali-induced degradant was followed. The dried precipitate was 
analyzed by IR and PMR and found to be 1-
phenylcyclopentanecarboxylic acid as a degradant (DG) and 2-
(diethylamino) ethoxy)methanol. 
Standard solutions and calibration 
Stock standard solutions were prepared by separately dissolving 25 
mg of PNX and DG in 50 ml of methanol. Further dilutions with 
methanol were carried out to obtain concentration ranges of 10-40 
µg ml-1and 10-40 µg ml-1 for PNX and DG respectively. These stock 
solutions were stored at 5°C. 
Triplicate 20 µl injections were made for each concentration of PNX 
and DG and chromategraphed under the conditions described above. 
The peak area of each concentration was plotted against the 
corresponding concentration to obtain the calibration graph. 
Sample preparation 
A volume of the syrup equivalent to 25 mg PNX was diluted to 50 ml 
with methanol. Further dilutions were carried out with the mobile 
phase to reach the calibration range of PNX. The general procedures 
for HPLC method described under calibration were followed and the 
concentration of PNX was calculated. 
Kinetic investigation of acidic and alkaline degradation 
Accurately weighed 20 mg of PNX was dissolved in 100 ml methanol. 
Separate 2 ml aliquots of the above solution were transferred into 
separate stoppered conical flasks and mixed with 2 ml of 0.2M 
sodium hydroxide or 2M hydrochloric acid. The flasks were placed 
in a thermostatic oven at different temperatures 
(60,70,80,85,90°C)for acidic and alkaline degradation for different 
time intervals. At the specified time intervals, the contents of the 
flasks were neutralized to pH 7 using predetermined volumes of 
0.2M sodium hydroxide and 2M hydrochloric acid solutions. The 
contents of the flasks were transferred into 10 ml volumetric flasks 
and diluted to the volume with mobile phase. Aliquots of 20 μl of 
each solution were chromatographed under the conditions 
described above and the concentrations of the remaining PNX were 
calculated at each temperature and time interval. 
pH- rate profile 
Accurately weighed 40 mg of PNX was transferred into 100 ml 
volumetric flask, dissolved and diluted to the volume with methanol. 
Separate 1 ml aliquot of PNX solution and 2 ml of the Britton-
Robinson buffer solutions [18] were transferred into stoppered 
conical flasks. The pH values of the buffer solutions used for 
measurement of the pH-rate profile of the degradation of PNX were 
as follows: 2.1, 3, 4, 5, 5.7, 6.5, 7.7, 9.2, 10.7 and 12. The flasks were 
placed in a thermostatic oven at 70 °C for different time intervals. At 
the specified time intervals the contents of flasks were neutralized 
using 1M sodium hydroxide or 1M hydrochloric acid solutions. The 
contents of flasks were transferred into 10 ml volumetric flasks and 
diluted to volume with the mobile phase. Aliquot of 20 µl of each 
solution was chromategraphed under the conditions described 
above and the concentrations of the remaining PNX was calculated 
at each pH value and time interval. 
RESULTS AND DISCUSSION 
Identification of the degradant 
When PNX was boiled with 0.1 M sodium hydroxide for 3 h or 1M 
hydrochloric acid for 12 h, 1-phenylcyclopentanecarboxylic acid 
(DG) and 2-(diethylamino) ethoxy) methanol could be isolated from 
the reaction mixture as degradants of PNX. 
The suggested pathway for the degradation of PNX in 0.1M sodium 
hydroxide and 1M hydrochloric acid is presented in scheme 1.  
The assignment of the degradant DG as 1-
phenylcyclopentanecarboxylic acid was based on the comparison of 
the IR and PMR spectral data of the purified specimens, separated 
from the degradation reaction, with those of the intact PNX.  
The IR spectrum (KBr) of PNX was characterized by the absorption 
frequency of C=O ester band at 1726.94 cm-1. On the other hand the 
IR spectrum (KBr) of DG revealed the OH Association and C=O 
stretching at 3416.28 and 1685.48 cm-1 respectively. Moreover, the 
spectrum of DG lacks the characteristic ester C=O. The IR spectrum 
of the alcoholic part isolated from PNX degradation characterized by 
OH Association at 3445.21 cm-1. 
The PMR spectrum of PNX in dimethyl sulphoxide characterized by 
the appearance of the protons at: δ(ppm(= 1.02 (t,6H,(CH3)2),1.6-
1.73(t,4H,(CH2)2cyclopentane), 1.9-2.06 (t, 4H, (CH2)2 cyclopentane), 
2.5 (q, 4H, (CH2)2), 2.54 (t,2H,CH2-N),3.5 (t,2H,CH2-O), 3.6(t,2H,CH2-
O), 4.1 (t, 2H, CH2-O)and 7.23-7.33(m,5H,Ar-H). While the PMR 
spectrum of DG in the same solvent characterized by the appearance 
of the protons at: δ(ppm)=1.6-1.73(t,4H,(CH2)2cyclopentane),1.9-
2.06(t,4H,(CH2)2cyclopentane),7.23-7.33(m,5H,Ar-H) and 10.4 (s, 
1H, COOH). It is obviously from this PMR that DG lacks the alcoholic 
part protons. Also, the PMR spectrum of alcoholic part shows the 
appearance of protons at: δ(ppm(= 1.02 (t, 6H, (CH3)2), 2.51 (q, 4H, 
(CH2)2), 2.54 (t, 2H, CH2-N), 3.5 (t, 2H, CH2-O), 3.53 (t, 2H, CH2-O), 3.7 













Scheme 1: Mechanism of hydrolysis of PNX in 1 M hydrochloric acid and 0.1 M
sodium hydroxide.  
Assay parameters 
The UV absorption spectra of PNX and its degradant DG are 
overlapped (Fig.1). While the alcohol part is aliphatic and it has no 
UV absorption spectrum. The simultaneous determination of PNX 
and DG by conventional, derivative and derivative ratio 
spectrophotometry is hindered by strong spectral overlap 
throughout the wavelength range. The proposed HPLC method was 
used to resolve a complex mixture of such compounds. 
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The developed HPLC method was applied for the separation of PNX 
and DG. To optimize the LC assay parameters, the mobile phase 
composition was studied. A satisfactory separation was obtained by 
using a mobile phase consisting of methanol and 10 mM sodium 
dihydrogen phosphate pH 4, adjusted with sodium hydroxide in 
ratio of (60:40 v/v). It was found that, increasing methanol 
concentration to more than 80% caused inadequate separation of 
PNX and its degradant. While decreasing methanol concentration to 
less than 40% separation has occurred but with excessive tailing for 
PNX and DG. Variation of pH of the mobile phase did not have 
significant effect on chromatographic resolution of DG peak 
revealing the stability of DG peak to pH variation. 
 
Fig. 1: UV absorption spectra of 20 μg ml-1 of PNX (––––) and 20 
μg ml-1 of DG (------) in methanol. 
Quantitation was achieved with UV detection at 230 nm based on 
peak area. The specificity of the LC method is illustrated in (Fig.2)  
Where complete separation of PNX and its degradant was noticed. 
The average retention time ± S. D. for DG, PNX were found to be 3.9 ± 
0.003 and 5.13 ± 0.004 min., respectively, for ten replicates. 
The system suitability test results of the developed method are given 
in Table 1. 
 
Fig. 2: A Typical HPLC chromatogram of 20µl injection of 
synthetic mixture of 25µg ml-1 of DG and 40 µg ml-1 of PNX. 
 
Table 1: The system suitability test results of the developed method for determination of PNX and DG. 










%RSD of retention time Plate count 
DG 3.90 1.79 1.49 (a1) 2.75 (b1) 1.06 0.24 4970 
PNX 5.13 2.66   1.09 0.25 7456 
The retention time of un retained peak is 1.2 min, a1, b1: are α and Rs calculated for DG and PNX. 
 
Kinetic investigation 
The kinetics of degradation of PNX were investigated in 0.1 M 
sodium hydroxide and 1M hydrochloric acid since the 
decomposition rate of PNX at lower strengths of hydrochloric acid 
was too slow to obtain reliable kinetic data. A regular decrease in the 
concentration of intact PNX with increasing time intervals was 
observed. At the selected temperatures, the acidic and alkaline 
degradation processes followed pseudo first order kinetics (Fig.3,4) 
respectively. From the slopes of the straight lines it was possible to 
calculate the apparent first order degradation rate constant and the 
half-life at each temperature for acidic and alkaline degradation 
processes of PNX (Table 2, 3) respectively. Plotting log Kobs values 
versus 1/T, the Arrhenius plots (Fig.5) were obtained and found to 
be linear in the temperature range 60– 90 °C for both the acidic and 
alkaline degradation. The activation energy was calculated for PNX 
and found to be 18.48 kcal mol-1 for acidic degradation process and 
15.96 kcal mol-1 for alkaline degradation process. 
 
 
Fig. 3: Pseudo first-order plots for the degradation of PNX in 1 M hydrochloric acid at various temperatures using HPLC method. 
Key: 60 (■);70(•), 80(▲);85 (□); 90(Ο), Ct, concentration at time t, and C°, concentration at zero time. 
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Fig. 4: Pseudo first-order plots for the degradation of PNX in 0.1 M 
sodium hydroxide at various temperatures using HPLC method. 
Key: 60 (■) ;70(•), 80(▲);85 (□); 90(Ο), Ct, concentration at time t, and 
C°, concentration at zero time. 
Fig. 5: Arrhenius plots for the degradation of PNX in 1M 
hydrochloric acid (■) and in 0.1M sodium hydroxide (▲) using the 
proposed HPLC method. 
 
Table 2: Degradation rate constant (Kobs) and half-life (t1/2) for 
PNX in 1M hydrochloric acid determined by the proposed HPLC. 
Temperature (°C) Kobs(h-1) t1/2(h) 
60 0.030 23.10 
70 0.072 9.63 
80 0.150 4.62 
85 0.210 3.30 
90 0.310 2.24 
 
Table 3: Degradation rate constant (Kobs) and half-life (t1/2) for PNX 
in 0.1 M sodium hydroxide determined by the proposed HPLC. 
Temperature (°C) Kobs(h-1) t1/2(h) 
60 0.100 6.93 
70 0.191 3.63 
80 0.380 1.82 
85 0.537 1.29 
90 0.720 0.96 
 
Fig. 6: pH-Rate profile for the decomposition of PNXin britton-
Robinson buffer at 70°C. 
 
Table 4: Degradation rate constant (kobs) and half-life (t1/2) for 
PNX in Britton-Robinson buffer at different pH values and 70 °C. 
pH kobs (h-1) t1/2(h) 
2.1 0.825 0.840 
3 0.341 2.035 
4 0.238 2.913 
5 0.192 3.612 
5.7 0.149 4.658 
6.5 0.375 1.848 
7.7 0.449 1.543 
9.2 0.518 1.339 
10.7 0.700 0.990 
12 1.107 0.626 
The pH-rate profiles of the degradation of PNX in Britton-Robinson 
buffer solutions were studied at 70°C (Fig.6). Britton-Robinson 
buffer solutions were used throughout the entire pH range in order 
to avoid possible effects of different buffer species. The apparent 
first order degradation rate constant and the half-life were 
calculated for each pH value (Table 4). PNX was found to be most 
stable at a pH of 5.7.  
Validation of the method 
Linearity 
The linearity of the LC detector response for determination of PNX 
and DG was evaluated by analyzing a series of different 
concentrations of each compound. Seven concentrations were 
chosen, ranging between 10-40µg ml-1and 10-40 µg ml-1for PNX and 
DG respectively. Each concentration was repeated three times; this 
approach provided information on the variation in peak area 
between samples of the same concentration. The linearity of the 
calibration graphs was validated by the high value of the correlation 
coefficient and the intercept value, which was not statistically 
(*p<0.05) different from zero. Characteristic parameters for 
regression equations obtained by least squares treatment of the 
results are given in Table 5. 
 
Table 5: Characteristic parameters for the regression equations 
of the proposed HPLC for determination of PNX and DG 
Parameters PNX DG 
Linearity (μg ml-1) 10-4 0 10-4 0 
Detection limit (μg ml-1) 3.79 x10-2 4.24 x10-2 









Standard deviation of the slope (Sb) 6.22 x10-2 7.99 x 10-2 
Relative standard deviation of the slope 
(%) 
1.67 1.87 
Confidence limit of the slope b 3.65 – 
3.84 
4.18-4.38 
Intercept (a) -1.07 -0.25 
Standard deviation of the intercept (Sa) 2.33 2.91 
Confidence limit of the intercept b -3.19 –
3.65 
-2.89-2.39 
Correlation coefficient (r) 0.9998 0.9998 
Standard error of estimation 0.81 1.01 
aY = a+bC,where C is the concentration of PNX and DG in μg ml-1and 
Y is the peak area in the HPLC method. 
b 95% confidence limit. 
Ali et al. 





For evaluation of the precision estimates, repeatability and 
intermediate precision were performed at three concentration levels 
for each compound. The data for each concentration level were 
evaluated by one-way ANOVA. An 8 days x 2 replicates design was 
performed (Table 6). Statistical comparison of the results was 
performed using the P-value of the F-test. Three univariate analyses 
of variance for each concentration level were made. Since the P-
value of the F-test is always greater than 0.05, there is no 
statistically significant difference between the mean results obtained 
from one level of day to another at the 95 % confidence level. 
 
Table 6: Analysis of variance for repeatability and intermediate precision for PNX and DG by the proposed HPLC method 
Compound Conc. Level Sources of variance Sum of squares DF MS F-ratio P-value 
PNX 10μg ml-1 Between 9.65 7 1.37 1.28 0.59 
Within 14.11 8 1.76   
Total 23.76 15    
PNX 25 μg ml-1 Between 4.22 7 0.60 1.97 0.82 
Within 9.45 8 1.18   
Total 13.67 15    
PNX 40μg ml-1 Between 8.66 7 1.23 1.52 0.45 
Within 6.45 8 0.81   
Total 15.11 15    
DG 10μg ml-1 Between 8.01 7.00 1.14 1.23 0.70 
Within 11.20 8.00 1.40   
Total 19.21 15.00    
DG 25 μg ml-1 Between 6.13 7.00 0.88 1.58 0.77 
Within 11.12 8.00 1.39   
Total 17.33 15.00    
DG 40 μg ml-1 Between 3.95 7.00 0.56 2.32 0.91 
Within 10.40 8.00 1.30   
Total 14.35 15.00    
Where, DF is the degree of freedom and MS is the mean square. 
The critical value of F-ratio is 3.5 and P-value is 0.05. 
 
Range 
The calibration range was established through consideration of the 
practical range necessary, according to each compound 
concentration present in pharmaceutical product, to give accurate, 
precise and linear results. The calibration range of each compound is 
given in Table 5. 
Detection and quantitative limits 
According to ICH recommendations [19], the approach based on the 
S.D. of the response and the slope was used for determining the 
detection and quantitative limits. The theoretical values were 
assessed practically and are given in Table 5. 
Selectivity 
Method selectivity was achieved by preparing different mixtures of 
PNX and DG within the linearity range concentration. The laboratory 
prepared mixtures were analyzed according to the previous 
procedure described under the proposed HPLC method. Satisfactory 
results were obtained (Table 7), indicating the high selectivity of the 
proposed method for determination of PNX and DG. 
 
Table 7: Determination of PNX and DG in laboratory prepared mixtures using the proposed HPLC method. 
Exp. No Conc. of (PNX) 
(μgml-1) 
Conc. of (DG) (μgml-1) % Recovery 
PNX DG 
1 25 40 101.1 100.8 
2 10 35 101.2 100.5 
3 15 30 99.2 98.7 
4 20 25 100.4 99.5 
5 35 20 100.1 100.9 
6 30 15 99.6 100.1 
7 40 10 100.5 99.7 
  Mean 100.30 100.03 
  S. D 0.68 0.73 
 
Table 8: Application of the standard addition technique on Cabella® syrup to the analysis of PNX and DG by the proposed HPLC method 
Exp. No Conc. of (PNX) Conc. of added (DG) (μgml-1) % Recovery 
Claimed (μgml-1) Added (μgml-1) PNX DG 
1 10 20 10 99.6 100.1 
2 20 10 15 100.6 100.9 
3 25 10 20 99.2 99.8 
4 15 10 25 99.75 101.1 
5 10 10 30 101.3 99.6 
6 20 20 40 101.1 98.9 
   Mean 100.23 100.07 




This study was performed by addition of known amounts of PNX and 
DG to a known concentration of the commercial syrup (standard 
addition method). The resulting mixtures were assayed and results 
obtained for PNX and DG were compared with expected results. 
Excellent recoveries of standard addition method (Table 8) suggest 
that good accuracy of the HPLC proposed method. 
Robustness 
To determine the robustness of the developed method, experimental 
conditions were purposely altered and the resolution between PNX 
and DG was evaluated. The flow rate of the mobile phase was 1 ml 
min-1. To study the effect of flow rate on the resolution, it was 
changed by 0.2 units from 0.8 to 1.2 ml min-1, while the mobile phase 
components were held constant. The effect of percent of organic 
strength on resolution was studied by varying methanol from 57 to 
63%. Also pH of the 10 mM potassium dihydrogen phosphate was 
varied by ±0.2 units. In all the deliberate varied chromatographic 
conditions (flow rate, percentage organic strength and pH), the 
resolution between PNX and its degradant (DG) was not altered, 
illustrating robustness of the method. 
Stability 
The stability of PNX and DG standard solutions in the mobile phase 
was evaluated by leaving the standard solutions in tightly capped 
volumetric flasks, protected from light, on a laboratory bench and in 
the refrigerator. The studied compound solutions in mobile phase 
exhibited no chromatographic changes for 24 hours when kept at 
room temperature and for 7 days when stored refrigerated at 5°C. 
Analysis of Pharmaceutical product 
The proposed HPLC method was applied to determination of PNX in 
freshly prepared commercial syrup (Table 9).  
Also, expired commercial syrup was analyzed by the proposed 
method and the mean percentage of PNX ± S. D. (n=7) was found to 
be 87.0 ± 1.04. The HPLC chromatogram of expired commercial 
syrup showes the peak of the degradation product of PNX (Fig.7). 
 
 
Fig. 7: Chromatogram of expired PNX syrup solution containing 
PNX and its degradant DG. 
 
Table 9: Determination of PNX in Cabella® syrup using 
proposed HPLC method 
Sample No Concentration (μg ml-1) % Recovery a 
1 10 98.8 
2 15 100.8 
3 20 99.4 
4 25 101.2 
5 25 99.0 
6 30 99.1 
7 35 98.1 
 Mean 99.49 
 S. D 1.03 
 R. S. D 1.04 
aMean and S. D. for seven determinations; percentage recovery from 
the label claim amount. 
The results of determination of PNX in syrup obtained from the 
proposed HPLC method were compared with those of a published 
HPLC method [14] which uses 5 µm particle size, C18-bonded silica 
column and mixture (60:40,v/v) of acetonitrile and water as the 
mobile phase and UV detection. Statistical comparison of the results 
was performed with regards to accuracy and precision using 
Student’s t-test and the F-ratio test at 95% confidence level (Table 
10). It is clear from this table that there is no significant difference 
between the proposed HPLC method and the published method with 
regard to accuracy and precision. 
 
Table 10: Statistical comparison between the proposed HPLC 
method and the published HPLC method for the determination 
of PNX in Cabella® syrup [14] 
 Mean found ±SDa 




99.49 ± 1.03 100.74 ± 1.45 
t 1.86 (2.18)b 
F 1.89 (4.28)b 
aMean and S. D. for seven determinations; percentage recovery from 
the label claim amount. 
bTheoretical values for t and F at *P <0.05 level. 
 
CONCLUSION 
The proposed HPLC method provides simple, accurate and 
reproducible quantitative analysis for the determination of PNX in 
pharmaceutical syrup, without any interference from the excipients, 
and in the presence of its acidic and alkaline degradation products. It 
was found that PNX is rapidly degraded in alkaline medium, while it 
is more stable in an acid medium. The most stability of PNX was 
found to be at pH 5.7. 
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